Sana
“Can engineered hypoimmune cells eliminate the need for lifelong immunosuppression and deliver durable cures for type 1 diabetes and B-cell cancers?”
Founded2018
HQSeattle, Washington, USA
Latest roundPost-IPO Equity
IndustryVertical SaaS / Healthcare
The story
Founded in 2018, Sana Biotechnology is a clinical-stage biotech developing engineered cells as medicines, targeting diseases such as type 1 diabetes, B-cell cancers, and B-cell autoimmune disorders. The company went public on Nasdaq in 2021 and has since advanced multiple clinical programs including hypoimmune ex vivo cell therapies and in vivo CAR T programs. As a pre-revenue clinical-stage company, its financial infrastructure centers on treasury management and cash preservation rather than embedded finance products for customers.
Last 12 months
2026-03
Product timeline
2018
Sana Biotechnology, Inc. incorporated in Delaware, focused on engineered cells as medicines.· pivot
2021
IPO on Nasdaq Global Select Market under ticker SANA.· ipo
2024
Enrolled patients in GLEAM (SC291, B-cell autoimmune) and VIVID (SC262, B-cell malignancies) trials; completed $189.8M financing.· banking
2025
New England Journal of Medicine published positive 12-week UP421 type 1 diabetes clinical results; significant progress on SC451 stem cell-derived islet program.· pivot
2026
Announced strategic collaboration with Mayo Clinic on SC451; continued progress toward Phase 1 trial for SC451 and SG293.· pivot
Regulated entities
Nasdaq-listed public company
US · 2021
Sana Biotechnology, Inc.
The stack
Ledger
Accounting gap: none